TRDA earnings date and last-quarter result: last quarter beat, P/E -1.54. Updated 2026-07-23.
Entrada Therapeutics (TRDA) Research Hub
Entrada Therapeutics (TRDA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.75 USD (+7.71%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.54, market cap 0.24B. This hub links to the full technical, earnings and options research available for TRDA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.75 USD (+7.71%) |
| 52-week range | 4.109 USD – 8.1 USD |
| Trend regime | Range |
| 14-day RSI | 41.3 (Bearish) |
| Trailing P/E | -1.54 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
Available research for TRDA
Covered Call on TRDA: how it works, illustrative setup around the real 4.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TRDA: how it works, illustrative setup around the real 4.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TRDA: how it works, illustrative setup around the real 4.75 USD price, max profit/loss, breakeven and when to use it. Educational.
TRDA technical analysis: range, last 4.75 USD, RSI 41.3, 52w range 4.109 USD–8.1 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TRDA in?
Entrada Therapeutics (TRDA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TRDA in an uptrend or downtrend?
As of 2026-10-26, TRDA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TRDA's trailing P/E ratio?
TRDA's trailing P/E is -1.54, with a market cap of 0.24B. See the earnings research page for full valuation detail.